Ischemic Optic Neuropathy
Conditions
Keywords
Bosentan
Brief summary
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years. The visual prognosis of the condition is unfavorable in the great majority of cases, with significant effects on the visual field and vision. The severity of the unilateral condition is also associated with bilateralization in 15% at 5 years. There is no effective treatment for the acute phase of the disease or to reduce the rate of bilateralization. In this context, it is essential to develop new therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve damage.
Detailed description
The main objective of our study will be to compare the treatment with bosentan to placebo for 8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional (visual acuity, visual field). The primary endpoint will be the improvement of the visual field, a major criterion of the affected visual function in this disease. The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the effectiveness of drug treatment in the absence of continuous positive airway pressure (set up after three months if necessary, feasible confounding factor for the evaluation of results ), the period of three months is sufficient to assess the anatomical and functional recovery (disappearance of papilledema).
Interventions
DRUGbosentan
treatment by bosentan or placebo is randomized , 125 mg twice a day
DRUGplacebo
treatment by bosentan or placebo is randomized
Sponsors
University Hospital, Grenoble
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non arteritic ischemic optic neuropathy (NAION) with onset \< 21 days * Age ≥ 50 years old * Signed informed consent form * Patients affiliated with a national health insurance scheme or beneficiaries of such a scheme
Exclusion criteria
* Pregnant women, women in labour or breast-feeding mother * Patients with other acute or chronic intercurrent ocular pathology interfering with visual acuity or visual field (diabetes, drug-induced or other retinopathy, other optic neuropathy including uni- or contralateral glaucoma and/or intraocular pressure \> 30 mmHg, advanced cataract, corneal opacities, amblyopia \< 5/10, severe myopia \> -6 diopters, retinal disease) * Simultaneous bilateral NAAION, 1 month apart or less * Signs that may raise suspicion of other inflammatory neuropathy: arterial NAAION (Horton's disease), pain on eye movement or any signs suggestive of optic neuritis, known diagnosis of multiple sclerosis, history of inflammatory optic neuropathy (homo- or ipsi-lateral). A temporal artery biopsy should be performed if there are symptoms suggestive of Horton's disease, or if there is pale and/or diffuse edema, or obliteration of the associated central retinal artery. * Patients with systolic blood pressure below 100 mmHg * Patient with orthostatic hypotension (20 mmHg drop in SBP and/or 10 mmHg drop in DBP when moving to a standing position) * Neurological history of vascular or tumour-related changes to the visual field or other optic neuropathy * Systemic inflammatory disease * Known allergy to bosentan * Patients with moderate to severe hepatic impairment (Child-Pugh class B or C), biliary cirrhosis (serum levels of liver aminotransferases, aspartate aminotransferases (ASAT) and/or alanine aminotransferases (ALAT), greater than three times the upper limit of normal, bilirubin greater than twice normal) * Estimated glomerular filtration rate (GFR) \< 30 ml/min/1.73 m2 * Patients treated with drugs whose efficacy may be reduced by activation of cytochrome P450, 2C9, 3A4 and 2C19 isoenzymes * Patients treated with amiodarone * Patient treated with systemic corticosteroids (background treatment or treatment initiated at the time of NAAION diagnosis) * Person deprived of liberty by judicial or administrative decision, adult protected by law, hospitalized person * Ongoing participation in another clinical research study or in the exclusion period of another clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mean deviation of automated visual field | 3 month | Humphrey 30-2 SITA-standard |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| visual acuity | 6, 12 and 24 month | ETDRS scale |
| optic nerve fiber layer thickness | 3, 6, 12 and 24 month | OCT measurement |
| mean deviation of automated visual field for healthy eye and NAION eye | 3, 6, 12 and 24 month | Humphrey 30-2 |
| inflammatory marker and prepro-endothelin dosing | 3 month | RANTES, MCP-1, TNF-α, INF-γ, IL-6, IL-10 and TGF-β |
| mean deviation of automated visual field for controlateral eye | 24 month | Humphrey 30-2 sita-standard |
| VFQ-25 score | 3 and 12 month | VFQ-25 quality of life |
| rate of bilateral occurence of NAION | at 24 month visit | rate of bilateralization |
Countries
France
Contacts
Primary ContactChristophe Pr CHIQUET, Prof, MD, PhD
Backup ContactBOUZEID Mayssam, PhD
Outcome results
None listed